MTR Corp Ltd/ HK0066009694 /
2024-11-08 12:00:00 AM | Chg. -0.25 | Volume | Bid9:08:43 AM | Ask9:08:43 AM | Market Capitalization | Dividend Y. | P/E Ratio |
---|---|---|---|---|---|---|---|
28.20HKD | -0.88% | 2.83 mill. Turnover: 78.68 mill. |
28.20Bid Size: - | 28.25Ask Size: - | 175.32 bill.HKD | 4.65% | 22.38 |
GlobeNewswire
04-16
Evidence for Clene’s CNM-Au8® as a Treatment for Repair and Remyelination in Multiple Sclerosis Pres...
GlobeNewswire
03-26
Attovia Enhances Clinical and Development Expertise with Appointment of Chief Medical Officer and Cl...
GlobeNewswire
03-07
Cara Therapeutics to Host Notalgia Paresthetica (NP) Virtual KOL Event on Wednesday, March 27, 2024
Newsfile Corp
01-19
Silicon Valley's Finest Startups Set to Ride HKSTP Elevator Pitch Competition 2024 to Asia and the W...
Newsfile Corp
2023-11-24
Dorsett Wanchai, Hong Kong Recognized for Sustainable Excellence and Exceptional Service
GlobeNewswire
2022-03-08
Cara Therapeutics Announces Oral KORSUVA™ (difelikefalin) Data Selected for Late-Breaking Presentati...
GlobeNewswire
2022-03-01
Cara Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results
GlobeNewswire
2022-02-08
Telix Expands Lutetium-177 Network with Eckert & Ziegler Clinical Supply Agreement
GlobeNewswire
2022-01-27
Telix and Biokosmos Sign Distribution Agreement for Prostate Cancer Imaging in Greece and Cyprus
GlobeNewswire
2021-12-22
Telix Collaborates with Olivia Newton-John Cancer Research Institute on Brain Cancer Imaging Study
GlobeNewswire
2021-12-20
First Patient Dosed in Study of Targeted Alpha Therapy Candidate for Bladder Cancer
GlobeNewswire
2021-12-07
Telix and NUCLIBER Sign Distribution Agreement for Prostate Cancer Imaging in Spain